Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.| MedCity News
Stephanie Baum is the Director of Special Projects for MedCityNews. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's worked for Dow Jones & Co., The Legal Intelligencer, The Christian Science Monitor, AP Radio's London bureau, and United Business Media. LinkedIn: https://www.linkedin.com/in/stephanie-baum-24a7406/| MedCity News
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.| MedCity News
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.| MedCity News
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.| MedCity News
NOWDiagnostics’ First To Know has FDA De Novo marketing authorization as a new test for syphilis. The at-home product needs only a single drop of blood to test for this sexually transmitted infection.| MedCity News
presented by | MedCity News
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.| MedCity News